 TORRANCE, Calif., Aug. 10, 2021 PRNewswire -- Emmaus Life Sciences, Inc. OTC: EMMA, a leader in sickle cell disease treatment, announced today that it has restated its financial statements for the fiscal year ended December 31, 2020, and that investors should no longer rely upon the financial statements included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission SEC on May 4, 2021. 